0ND5 vs NOVO-B: Side-by-Side Comparison
Compare H Lundbeck A/S (0ND5) and Novo Nordisk A/S (NOVO-B) side by side: valuation, financials, growth and model signals on Bullrun.
| Metric | 0ND5 | NOVO-B |
|---|---|---|
| Company | H Lundbeck A/S | Novo Nordisk A/S |
| Country / Exchange | Denmark · LSE | Denmark · CO |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General |
| Market cap | — | DKK 1.39T |
| P/E ratio | — | 11.5 |
| Dividend yield | — | 5.00% |
| Valuation model | — | 21.7% undervalued |
| Revenue (FY2025) | DKK 24.63B | DKK 309.06B |
| Revenue growth YoY | +11.9% | +6.4% |
| Net income | DKK 3.19B | DKK 102.43B |
| Gross margin | 82.7% | 81.0% |
| Diluted EPS | 3.22 | 23.03 |